Acadia Healthcare Company, Inc. - Form 8-K Summary
Business Context and Reporting Period
This Current Report on Form 8-K was filed on July 5, 2023, covering events occurring between June 28, 2023, and July 5, 2023. The filing primarily addresses significant changes in executive leadership under Item 5.02, including the appointment of a new General Counsel and the departures of the Chief Financial Officer, Executive Vice President of Finance, and the outgoing General Counsel.
Key Financial Metrics
The filing does not provide revenue, profit, cash flow, margin, debt, or liquidity metrics. It is a current report focused on corporate governance and personnel changes rather than financial performance.
Material Changes and Executive Transitions
- Appointment: Brian Farley was appointed Executive Vice President and General Counsel, effective July 26, 2023. He joins from GoHealth, Inc., where he served as Chief Legal Officer.
- Retirement (Chris Howard): Chris Howard, Executive Vice President, General Counsel, and Secretary, will retire effective July 26, 2023. He will provide transition services through July 31, 2023, and remain available for advisory services until February 24, 2024. He will receive a monthly fee of $10,591.88 during the transition period and remains eligible for 2021 performance-based equity awards.
- Departure (David Duckworth): David Duckworth resigned as Chief Financial Officer, effective July 10, 2023. He will provide transition services through July 31, 2023, and remain available until the filing of the 2023 Form 10-K. He will receive a monthly fee of $11,574.89 during the transition period and remains eligible for 2021 performance-based equity awards.
- Departure (Larry Harrod): Larry Harrod resigned as Executive Vice President of Finance, effective June 30, 2023. He will provide transition services through December 31, 2023, for a monthly payment of $10,309.87. He is eligible for a prorated 2023 annual cash bonus.
Guidance, Outlook, and Risks
The filing contains no financial guidance, outlook, or management commentary regarding future business performance. The primary risks disclosed relate to the transition of key executive roles and the associated separation agreements, which include extended non-competition and non-solicitation covenants for the departing officers.
Investor Verification Checklist
- Verify the effective dates of the new CFO and General Counsel appointments to ensure continuity of financial reporting and legal oversight.
- Review the attached separation agreements (Exhibits 10.1, 10.2, and 10.3) for full details on severance, transition fees, and equity vesting conditions.
- Monitor upcoming filings for the appointment of a permanent Chief Financial Officer to replace David Duckworth.
- Confirm the impact of these leadership changes on the company's strategic initiatives and regulatory compliance posture.